Literature DB >> 19129282

Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis.

G Devouassoux1, V Cottin, H Lioté, E Marchand, I Frachon, A Schuller, F Béjui-Thivolet, J-F Cordier.   

Abstract

The characteristics of patients with rheumatoid arthritis (RA) who develop obliterative bronchiolitis characterised by severe airflow obstruction have been hitherto poorly investigated. A retrospective study of 25 patients with RA and functional evidence of obliterative bronchiolitis (forced expiratory volume in one second (FEV(1))/forced vital capacity (FVC) <50% and/or residual volume (RV)/total lung capacity (TLC) >140% predicted) was conducted. Patients (mean+/-SD age 64+/-11 yrs) included 17 never-smokers and eight ex-smokers (10.5+/-5.4 pack-yrs). The diagnosis of RA preceded respiratory symptoms in 88% of cases. Dyspnoea on exertion was present in all patients and bronchorrhea in 44%. High-resolution computed tomography findings included: bronchial wall thickening (96%), bronchiectasis (40%), mosaic pattern (40%), centrilobular emphysema (56%), and reticular and/or ground-glass opacities (32%). Pulmonary function tests showed: FEV(1) 41+/-12% pred, FEV(1)/FVC 49+/-14%, FVC 70+/-20% pred, RV 148+/-68% pred and RV/TLC 142+/-34% pred. Lung biopsy, available in nine patients, demonstrated constrictive, follicular and mixed bronchiolitis. Patients were followed for 48.2+/-49 months. Treatment was poorly effective. Chronic respiratory failure occurred in 40% of patients, and four patients died. Obliterative bronchiolitis associated with rheumatoid arthritis is a severe and under-recognised condition leading to respiratory failure and death in a high proportion of patients.

Entities:  

Mesh:

Year:  2009        PMID: 19129282     DOI: 10.1183/09031936.00091608

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  22 in total

Review 1.  Advances in the medical treatment of rheumatoid arthritis.

Authors:  J Michelle Kahlenberg; David A Fox
Journal:  Hand Clin       Date:  2011-02       Impact factor: 1.907

2.  Follicular bronchiolitis in primary ciliary dyskinesia.

Authors:  Prashanth M Thalanayar; Fernando Holguin
Journal:  Australas Med J       Date:  2014-07-31

Review 3.  Lung disease in rheumatoid arthritis.

Authors:  Zulma X Yunt; Joshua J Solomon
Journal:  Rheum Dis Clin North Am       Date:  2015-02-03       Impact factor: 2.670

4.  Clinical Significance of Forced Oscillation Technique for Evaluation of Small Airway Disease in Interstitial Lung Diseases.

Authors:  Masashi Mikamo; Tomoyuki Fujisawa; Yoshiyuki Oyama; Masato Kono; Noriyuki Enomoto; Yutaro Nakamura; Naoki Inui; Hiromitsu Sumikawa; Takeshi Johkoh; Takafumi Suda
Journal:  Lung       Date:  2016-10-12       Impact factor: 2.584

Review 5.  Lung Manifestations in the Rheumatic Diseases.

Authors:  Tracy J Doyle; Paul F Dellaripa
Journal:  Chest       Date:  2017-05-25       Impact factor: 9.410

6.  FEV1 over time in patients with connective tissue disease-related bronchiolitis.

Authors:  Evans R Fernández Pérez; Mahalakshmi Krishnamoorthy; Kevin K Brown; Tristan J Huie; Aryeh Fischer; Joshua J Solomon; Richard T Meehan; Amy L Olson; Rosane Duarte Achcar; Jeffrey J Swigris
Journal:  Respir Med       Date:  2013-04-10       Impact factor: 3.415

Review 7.  Interstitial lung disease in patients with rheumatoid arthritis: spontaneous and drug induced.

Authors:  Robert W Hallowell; Maureen R Horton
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 8.  Follicular Bronchiolitis: A Literature Review.

Authors:  Basheer Tashtoush; Ndubuisi C Okafor; Jose F Ramirez; Laurence Smolley
Journal:  J Clin Diagn Res       Date:  2015-09-01

9.  Diagnosis and treatment of constrictive bronchiolitis.

Authors:  Gary R Epler
Journal:  F1000 Med Rep       Date:  2010-04-27

Review 10.  The pathogenesis of COPD and IPF: distinct horns of the same devil?

Authors:  Marco Chilosi; Venerino Poletti; Andrea Rossi
Journal:  Respir Res       Date:  2012-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.